BamSEC and AlphaSense Join Forces
Learn More

Nurix Therapeutics Inc. – Material Contracts

NASDAQ: NRIX    
Share price (5/22/26): $17.50    
Market cap (5/22/26): $1.810 billion
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 8-K 3 pages Amendment No. 3 to the Equity Distribution Agreement
12/34/56
EX-10.1
from 10-Q 11 pages This First Amendment to Sublease (This “Amendment”) Dated May 31, 2025 (The “Effective Date”) Is Made by and Between Janssen Research & Development, LLC, a New Jersey Limited Liability Company, Having an Address at 410 George Stret, New Brunswick, New Jersey 08901 (“Sublandlord”) and Nurix Therapeutics, Inc., a Delaware Corporation, Having an Address at 1700 Owens Street, Suite 205, San Francisco, California 94158 (“Subtenant”)
12/34/56
EX-10.1
from 10-Q 29 pages Certain Confidential Information Contained in This Document, Marked by [*], Has Been Omitted Because It Is Not Material and Would Likely Cause Competitive Harm to the Company if Publicly Disclosed. Sublease by and Between Janssen Research & Development, LLC, a New Jersey Limited Liability Company and Nurix Therapeutics, Inc., a Delaware Corporation Sublease
12/34/56
EX-10.1
from 8-K 4 pages Amendment No. 2 to the Equity Distribution Agreement
12/34/56
EX-10.4
from 10-Q 3 pages Third Amendment to Lease
12/34/56
EX-10.3
from 10-Q 4 pages Fifth Amendment to Lease
12/34/56
EX-10.2
from 10-Q 4 pages Fourth Amendment to Lease
12/34/56
EX-10.1
from 10-Q 5 pages Third Amendment to Lease
12/34/56
EX-10.1
from 8-K 7 pages Amendment No. 1 to the Equity Distribution Agreement
12/34/56
EX-10.2
from 10-Q 3 pages Second Amendment to Lease
12/34/56
EX-10.1
from 10-Q 4 pages Certain Confidential Information Contained in This Document, Marked by [*], Has Been Omitted Because It Is Not Material and Would Likely Cause Competitive Harm to the Company if Publicly Disclosed. Sixth Amendment to Collaboration and License Agreement
12/34/56
EX-10.25
from 10-K 105 pages Certain Confidential Information Contained in This Document, Marked by [*], Has Been Omitted Because It Is Not Material and Would Likely Cause Competitive Harm to the Company if Publicly Disclosed. Collaboration and License Agreement by and Between Nurix Therapeutics, Inc. and Seagen Inc. Dated as of September 6, 2023
12/34/56
EX-10.24
from 10-K 6 pages Certain Confidential Information Contained in This Document, Marked by [*], Has Been Omitted Because It Is Not Material and Would Likely Cause Competitive Harm to the Company if Publicly Disclosed. Fifth Amendment to Collaboration and License Agreement
12/34/56
EX-10.3
from 10-Q 107 pages Certain Confidential Information Contained in This Document, Marked by [*], Has Been Omitted Because It Is Not Material and Would Likely Cause Competitive Harm to the Company if Publicly Disclosed. Collaboration and License Agreement by and Between Nurix Therapeutics, Inc. and Seagen Inc. Dated as of September 6, 2023
12/34/56
EX-10.2
from 10-Q 3 pages First Amendment to Lease Agreement
12/34/56
EX-10.1
from 10-Q 3 pages First Amendment to Lease
12/34/56
EX-10.6
from 10-Q 8 pages Certain Information Contained in This Document, Marked by [*], Has Been Omitted Because It Is Not Material and Is the Type of Information the Registrant Treats as Private or Confidential. Fourth Amendment to Collaboration and License Agreement
12/34/56
EX-10.5
from 10-Q 3 pages Certain Information Contained in This Document, Marked by [*], Has Been Omitted Because It Is Not Material and Is the Type of Information the Registrant Treats as Private or Confidential. Third Amendment to Collaboration and License Agreement
12/34/56
EX-10.4
from 10-Q 4 pages Certain Information Contained in This Document, Marked by [*], Has Been Omitted Because It Is Not Material and Is the Type of Information the Registrant Treats as Private or Confidential. Second Amendment to Collaboration and License Agreement
12/34/56
EX-10.3
from 10-Q 3 pages Second Amendment to Collaboration, Option and License Agreement
12/34/56